Incretin-based Therapy in Early Diagnosed Type 1 Diabetes
NCT02908087 on ClinicalTrials.gov · last registry update 2022-01-11
A small phase 2 — 13 participants, against a typical 110. The sponsor logged completion for May 2021. Primary outcome, as filed: Serum C-peptide AUC. liraglutide is approved in the US, but not for type 1 diabetes — a registration here is not an approval, and most drugs tested in a new condition never get one for it.
- Status
- COMPLETED
- Phase
- P2
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- University of Oulu
- Sponsor type
- Other
- Enrollment
- 13
- Started
- 2016-03
- Primary completion
- 2021-05 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Serum C-peptide AUC
Conditions studied
Type 1 Diabetes
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.